Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
Soo-Kyung Cho, Hyoungyoung Kim, Yeo-Jin Song, Hye Won Kim, Eunwoo Nam, Shin-Seok Lee, Hye-Soon Lee, Sung-Hoon Park, Yeon-Ah Lee, Min-Chan Park, Sung Hae Chang, Hyoun-Ah Kim, Seung-Ki Kwok, Hae-Rim Kim, Hyun-Sook Kim, Bo Young Yoon, Wan-Sik Uhm, Yong-Gil Kim, Jae Hoon Kim, Jisoo Lee, Jeongim Choi, Yoon-Kyoung Sung
Korean J Intern Med. 2023;38(4):546-556. Published online 2023 Jun 20 DOI: https://doi.org/10.3904/kjim.2022.369
Citations to this article as recorded by 
Defining a Therapeutic Window of Opportunity in Alopecia Areata: Predictors of Early Response to Baricitinib
Daniel Muñoz-Barba, Carmen García-Moronta, Alberto Soto-Moreno, Manuel Sánchez-Díaz, Salvador Arias-Santiago
Journal of Clinical Medicine.2025; 14(20): 7312. CrossRef
Impact of age and cardiovascular risk factors on the incidence of adverse events in patients with rheumatoid arthritis treated with Janus Kinase inhibitors: data from a real-life multicentric cohort
Stefano Gentileschi, Carla Gaggiano, Arianna Damiani, Carmela Coccia, Pamela Bernardini, Massimiliano Cazzato, Francesco D’Alessandro, Giulia Vallifuoco, Riccardo Terribili, Marco Bardelli, Caterina Baldi, Luca Cantarini, Marta Mosca, Bruno Frediani, Sere
Clinical and Experimental Medicine.2024;[Epub] CrossRef
Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden
Hannah Bower, Thomas Frisell, Daniela di Giuseppe, Benedicte Delcoigne, Ulf Lindström, Carl Turesson, Katerina Chatzidionysiou, Elisabet Lindqvist, Ann Knight, Helena Forsblad-d'Elia, Johan Askling
RMD Open.2023; 9(4): e003648. CrossRef